SCHEMBL2080920

SCHEMBL2080920

CCOC(=O)c1nc(C2(OCCO)CCN(C(=O)c3ccccc3)CC2)[nH]c(=O)c1O

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.39
ELANE P08246 1/20 0.38
CHRM2 P08172 2/20 0.38
CHRM3 P20309 2/20 0.38
RNASEH1 O60930 1/20 0.38
KMT2A Q03164 3/20 0.37
GAA P10253 2/20 0.37
LMNA P02545 2/20 0.36
MAPT P10636 2/20 0.36
TSHR P16473 3/20 0.36
HPGD P15428 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
CRHBP P24387 1/20 0.36
CRHR2 Q13324 1/20 0.36
CRBN Q96SW2 1/20 0.36
CYP2D6 P10635 2/20 0.36
ACACB O00763 1/20 0.36
CYP3A4 P08684 1/20 0.36
CYP2C19 P33261 1/20 0.36
MEN1 O00255 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2081516 0.87 ENPP2 (0.43) ALDH1A1RNASEH1KMT2AGAAL3MBTL1
SCHEMBL2080125 0.84 CYP3A4 (0.35) ALDH1A1RNASEH1KMT2ALMNAMAPT
SCHEMBL2083125 0.84 ACACB (0.43) ALDH1A1RNASEH1KMT2AGAAACACB
SCHEMBL14064602 0.84 KDM4E (0.38) ALDH1A1RNASEH1KMT2AGAALMNA
SCHEMBL2079819 0.84 MAPT (0.34) ALDH1A1RNASEH1KMT2AGAAMAPT
SCHEMBL12864836 0.82 LMNA (0.36) ALDH1A1RNASEH1KMT2AGAALMNA
SCHEMBL1170226 0.82 LMNA (0.36) ALDH1A1RNASEH1KMT2AGAALMNA
SCHEMBL2079178 0.81 ALDH1A1 (0.34) ALDH1A1RNASEH1KMT2AGAAMAPT
SCHEMBL2080717 0.79 ALDH1A1 (0.43) ALDH1A1KMT2ALMNATSHRL3MBTL1
SCHEMBL1169665 0.79 KDM4E (0.34) ALDH1A1RNASEH1KMT2AGAALMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7897593-B2 HIV integrase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2011-03-01 US disclosed
US-7897593-B2 HIV integrase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2011-03-01 US disclosed
US-7897593-B2 HIV integrase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2011-03-01 US disclosed
WO-2007143446-A1 SPIRO-CONDENSED HETEROTRICYCLIC COMPOUNDS AS HIV INTEGRASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2007-12-13 WO disclosed
US-20070281917-A1 HIV Integrase Inhibitors BRISTOL-MYERS SQUIBB COMPANY 2007-12-06 US disclosed
US-20070281917-A1 HIV Integrase Inhibitors BRISTOL-MYERS SQUIBB COMPANY 2007-12-06 US disclosed
US-20070281917-A1 HIV Integrase Inhibitors BRISTOL-MYERS SQUIBB COMPANY 2007-12-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070281917-A1 HIV Integrase Inhibitors TYMP, POLN, IMPDH1 ALDH1A1 301/4885ELANE 1727/4885CHRM2 4870/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.